ストックスクリーナーアプリを入手
2.48
1.20%
-0.03
アフターアワーズ：
2.48
Insight Molecular Diagnostics Inc (IMDX) 最新ニュース
iMDx to Participate in NYC Investment Conferences September 811 - GlobeNewswire
iMDx Announces Participation in NYC Investment Conferences - AInvest
Molecular Diagnostics Leader iMDx Announces Double-Header NYC Investor Conference Schedule for September - Stock Titan
IMDX CFO Andrea James Featured in Empowered Patient Podcast on Democratizing Molecular Diagnostics - MarketScreener
HIV Diagnostics Market Size, Share & Forecast, 2025–2034 - Global Market Insights Inc.
Insight Molecular Diagnostics: Pioneering the Next Generation of Transplant Rejection Testing and FDA Readiness - AInvest
Veterinary Molecular Diagnostics Market on Track for Massive Expansion by 2035, Forecasts Reveal. - newstrail.com
Analysts Offer Insights on Healthcare Companies: Immatics (IMTX) and Insight Molecular Diagnostics (IMDX) - The Globe and Mail
Insight Molecular Diagnostics Inc. shares rise 12.92% intraday after Myriad Genetics appoints new CFO. - AInvest
Insight Molecular: Needham Reiterates Buy Rating with $4.25 PT - AInvest
Insight Molecular Diagnostics: Paving the Next Frontier in Transplant Rejection Testing with FDA-Ready Innovation - AInvest
IMDX’s GraftAssureDx Study: A Game-Changer in Kidney Transplant Monitoring? - TipRanks
Insight Molecular Diagnostics Inc. shares rise 1.21% intraday after Caris Life Sciences validates MI Cancer Seek® assay. - AInvest
Insight Molecular Diagnostics Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - simplywall.st
Insight Molecular Diagnostics : With Q&A (insight molecular diagnostics inc imdx us q2 2025 earnings call 11 august 2025 5 00 pm et) - MarketScreener
Lake Street Sticks to Their Buy Rating for Insight Molecular Diagnostics (IMDX) - The Globe and Mail
Insight Molecular Diagnostics Inc. shares fall 1.53% intraday after reporting a Q2 loss of $9.7 million. - AInvest
Insight Molecular Diagnostics Inc (IMDX) Q2 2025 Earnings Call Highlights: Strategic Advances ... - Yahoo Finance
Needham reiterates Buy rating on Insight Molecular Diagnostics stock By Investing.com - Investing.com Nigeria
Needham reiterates Buy rating on Insight Molecular Diagnostics stock - Investing.com India
Insight Molecular Diagnostics: Promising Future with GraftAssureIQ and Strategic Expansion - TipRanks
Insight Molecular Diagnostics: Q2 Earnings Snapshot - Connecticut Post
Insight Molecular Diagnostics Reports Q2 2025 Progress - TipRanks
IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch - Santé log
Earnings call transcript: Insight Molecular Diagnostics Q2 2025 reveals strategic advancements - Investing.com Canada
Insight Molecular Diagnostics Reports Q2 Loss of $9.7 Million - AInvest
IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx L - GuruFocus
In Insight Molecular Diagnostics Inc. Announces Graftassuredx Launch - MarketScreener
IMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics Conference - 富途牛牛
Insight Molecular Diagnostics Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView
Insight Molecular Diagnostics Inc.Common Stock (Nasdaq:IMDX) Stock Quote - FinancialContent
Molecular Diagnostics Market Overview: Growth Factors to 2035 - MarketReports.us
PCR Molecular Diagnostics Market Global Forecast 2025–2032: Sector-Wise Insights - newstrail.com
Insight Molecular Diagnostics Inc. shares rise 8.81% premarket after QIAGEN's solid Q2 2025 results. - AInvest
iMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics Conference - The Manila Times
iMDx to Release Second Quarter 2025 Results on August 11, - GlobeNewswire
iMDx Announces Two Major Investor Events: Q2 Earnings and Needham Conference Back-to-Back - Stock Titan
Diagnostic Contract Manufacturing Market Forecast 2025–2034: Key Metrics and Strategic Insights - WhaTech
IMDX World Transplant Congress Late-Breaking Data - GlobeNewswire
Revolutionary Transplant Test Achieves 79% Accuracy, Nearly Doubles Industry Standard in Detecting Organ Rejection - Stock Titan
U.S., Europe, and Asia Pacific Molecular Diagnostics Market - openPR.com
iMDx to Host Virtual KOL Event to Discuss its In-House - GlobeNewswire
Vanderbilt Professor Reveals Game-Changing In-House Kidney Transplant Testing Technology at Expert Event - Stock Titan
Analysts Are Bullish on Top Healthcare Stocks: ProMIS Neurosciences (PMN), Bruker (BRKR) - The Globe and Mail
Insight Molecular Diagnostics Inc. shares fall 3.16% intraday as ImmunoPrecise Antibodies Ltd. announces new findings. - AInvest
Insight Molecular Diagnostics Inc. shares rise 5.32% premarket after Seegene unveils new diagnostic system and data analytics platform. - AInvest
Insight Molecular Diagnostics Insiders Increase Holdings Amidst Bullish Bets - AInvest
Insight Molecular Diagnostics Insiders Placed Bullish Bets Worth US$2.82m - Yahoo Finance
U.S. In Vitro Diagnostics (IVD) Market and Competition - GlobeNewswire
U.S. In Vitro Diagnostics (IVD) Market and Competition Insights 2025-2034Next-Gen Genomic Tools and Decentralized Testing to Transform U.S. Diagnostics Landscape - Yahoo.co
0.51%
0.31%
大文字化:
|
ボリューム (24 時間):